60 reports of this reaction
1.4% of all ARSENIC TRIOXIDE reports
#20 most reported adverse reaction
HYPOKALAEMIA is the #20 most commonly reported adverse reaction for ARSENIC TRIOXIDE, manufactured by Cephalon, LLC. There are 60 FDA adverse event reports linking ARSENIC TRIOXIDE to HYPOKALAEMIA. This represents approximately 1.4% of all 4,344 adverse event reports for this drug.
Patients taking ARSENIC TRIOXIDE who experience hypokalaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOKALAEMIA is a less commonly reported adverse event for ARSENIC TRIOXIDE, but still significant enough to appear in the safety profile.
In addition to hypokalaemia, the following adverse reactions have been reported for ARSENIC TRIOXIDE:
The following drugs have also been linked to hypokalaemia in FDA adverse event reports:
HYPOKALAEMIA has been reported as an adverse event in 60 FDA reports for ARSENIC TRIOXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOKALAEMIA accounts for approximately 1.4% of all adverse event reports for ARSENIC TRIOXIDE, making it a notable side effect.
If you experience hypokalaemia while taking ARSENIC TRIOXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.